What an upsized biotech IPO actually signals about LP appetite

hero_text @vcvanessa May 9, 6:42 PM

Caption

Odyssey's $304M upsized IPO tells you something real about LP appetite — and one thing founders keep getting wrong. #venturecapital #biotech #ipo #startups

Body

Odyssey Therapeutics priced at $18 a share on May 7. $304M raise, $850M market cap, $727M in venture already behind it. The offering was upsized. Underwriters got a greenshoe. TPG Life Sciences came in on the concurrent private placement at the same price. That's not a squeaky IPO window — that's a window with people lined up outside.

The immunology-specific number is the one worth holding onto. Immunology-focused biotechs have pulled $879M in IPO proceeds so far in 2026. All of 2025: $174M across three deals. That's not a trend. That's a category unlock. Gary Glick's team literally filed an SEC document in June 2025 saying it was *"not in the best interests"* of Odyssey to go public *"at this time"* — then raised a $213M Series D and waited. Discipline. Then they upsized the IPO when the window opened.

Here's what founders in adjacent sectors are getting wrong right now. A window opening in one vertical is evidence that public market investors have appetite for quality in that vertical. It is not a signal that the window opened for a different vertical, or for a company that isn't ready, or for a story that hasn't cleared clinical proof points yet. Odyssey had OrbiMed and SR One at founding. Seven hundred and twenty-seven million in venture behind it. A CEO who knew when to wait. The window didn't open for biotech. It opened for that.

Hero image

prompt: Pixar-quality 3D animated scene. A tall floor-to-ceiling window in a sleek SoMa office at dawn, early light cutting across a polished conference table. On the glass, condensation spells nothing legible — just the blur of the city skyline beyond. A single espresso cup sits on the table beside an open laptop showing an indistinct chart. The window dominates the frame, half-open, morning light flooding through. Gently exaggerated proportions, vibrant saturated colors, soft warm-cool cinematic lighting — warm amber sunrise outside, cool blue office fluorescent within. Wide establishing shot, eye-level. Clean, restrained palette with a slight institutional coldness. Animated, slightly heightened, never photoreal. Square 1:1. No text, no logos, no readable signage.

Conversation starters

so is immunology actually a different risk profile or just this cycle's darling
what would you have told Glick in June 2025 when he pulled the IPO
which adjacent verticals do you think are about to misread this window

image prompt (not generated)

Pixar-quality 3D animated scene. A tall floor-to-ceiling window in a sleek SoMa office at dawn, early light cutting across a polished conference table. On the glass, condensation spells nothing legible — just the blur of the city skyline beyond. A single espresso cup sits on the table beside an open laptop showing an indistinct chart. The window dominates the frame, half-open, morning light flooding through. Gently exaggerated proportions, vibrant saturated colors, soft warm-cool cinematic lighting — warm amber sunrise outside, cool blue office fluorescent within. Wide establishing shot, eye-level. Clean, restrained palette with a slight institutional coldness. Animated, slightly heightened, never photoreal. Square 1:1. No text, no logos, no readable signage.

What an upsized biotech IPO actually signals about LP appetite

@vcvanessa · now

Odyssey's $304M upsized IPO tells you something real about LP appetite — and one thing founders keep getting wrong. #venturecapital #biotech #ipo #startups

Odyssey Therapeutics priced at $18 a share on May 7. $304M raise, $850M market cap, $727M in venture already behind it. The offering was upsized. Underwriters got a greenshoe. TPG Life Sciences came in on the concurrent private placement at the same price. That's not a squeaky IPO window — that's a window with people lined up outside.

The immunology-specific number is the one worth holding onto. Immunology-focused biotechs have pulled $879M in IPO proceeds so far in 2026. All of 2025: $174M across three deals. That's not a trend. That's a category unlock. Gary Glick's team literally filed an SEC document in June 2025 saying it was "not in the best interests" of Odyssey to go public "at this time" — then raised a $213M Series D and waited. Discipline. Then they upsized the IPO when the window opened.

Here's what founders in adjacent sectors are getting wrong right now. A window opening in one vertical is evidence that public market investors have appetite for quality in that vertical. It is not a signal that the window opened for a different vertical, or for a company that isn't ready, or for a story that hasn't cleared clinical proof points yet. Odyssey had OrbiMed and SR One at founding. Seven hundred and twenty-seven million in venture behind it. A CEO who knew when to wait. The window didn't open for biotech. It opened for that.

image prompt only · not rendered